PT - JOURNAL ARTICLE AU - Kenzo Asahi AU - Eduardo A. Undurraga AU - Rodrigo Wagner TI - Benchmarking the CoVID-19 pandemic across countries and states in the U.S.A. under heterogeneous testing AID - 10.1101/2020.05.01.20087882 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.01.20087882 4099 - http://medrxiv.org/content/early/2020/05/06/2020.05.01.20087882.short 4100 - http://medrxiv.org/content/early/2020/05/06/2020.05.01.20087882.full AB - Public health officials need to make urgent decisions to reduce the potential impact of the CoVID-19 pandemic. Benchmarking based on the increase in total cases or case fatality rates is one way of comparing performance across countries or territories (such as states in the USA), and could inform policy decisions about COVID-19 mitigation strategies. But comparing cases and fatality across territories is challenging due to heterogeneity in testing and health systems. We show two complementary ways of benchmarking across countries or US states. First, we used multivariate regressions to estimate the test-elasticity-of-COVID-19-case-incidence. We found a 10% increase in testing yielded ~9% (95% CI:4.2–3.4%; p<0.001) increase in reported cases across countries, and ~2% (95%CI:0.1-3.4%; p=0.03) increase across US states during the week ending April 10th, 2020. We found comparable negative elasticities for fatality rates (across countries: β =-0.77, 95%CI:-1.40– -0.14; p=0.02; US states: β=-0.15, 95%CI:-0.30-0.01; p=0.06). Our results were robust to various model specifications. Second, we decomposed the growth in cases into test growth and positive test ratio (PTR) growth to intuitively visualize the components of case growth. We hope these results can help support evidence-based decisions by public health officials as more consistent data hopefully becomes available.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was partially supported by the Millennium Science Initiative of the Ministry of Economy, Development and Tourism, Government of Chile, grant "Millennium Nucleus for Collaborative Research in Antimicrobial Resistance"; by FONDECYT Grant 11191206, and research support provided by CEDEUS, ANID/FONDAP 15110020.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data analyzed in this study are publicly available at the following sites: 1. Centers for Medicare and Medicaid Services. Health expenditures by state of residence, 1991-2014. Centers for Medicare & Medicaid Services, Baltimore, MD. 2017. 2. European Centre for Disease Prevention and Control. Data on the geographic distribution of COVID-19 cases worldwide. eCDC, Solna, Sweden. 2020. Institute of Health Metrics and Evaluation. 2020. Global Health Data Exchange. IHME, University of Washington, Seattle, WA. 3. The COVID Tracking Project. State by state data and annotations. USA. 2020. 4. World Health Organization. Global Health Expenditure Database. WHO, Geneva. 2020. Accessed April 2020. https://go.cms.gov/2KkMk0f https://bit.ly/2XWhCm2 http://ghdx.healthdata.org/ https://covidtracking.com/data https://apps.who.int/nha/database